SRSF2 and myeloproliferative disorder: SRSF2 mutations involving proline 95 residue (SRSF2P95) have been found in patients with various myeloid neoplasms including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), MPN and acute myeloid leukemia (AML) [14, 15].